Lantheus Holdings, Inc. · NASDAQ:LNTH
Lantheus — Merger or Acquisition (August 2026)
10 slides from Lantheus's merger presentation, Aug 3, 2026
Slide 1: Lantheus Announces Definitive Agreement to Merge with Curium
Exhibit 99.2 Lantheus Announces Definitive Agreement to Merge with Curium Combined company would span full radiopharmaceutical value chain delivering nuclear medicine solutions to patients and healthcare systems across more than 70 countries August 3, 2026 © 2026 Lantheus. All rights reserved.
Slide 2: Safe Harbor Statements
Safe Harbor Statements Additional Information and Where to Find it In connection with the proposed acquisition of Lantheus Holdings, Inc. (the “Company”) by Curium US Holdings LLC (“Parent”), the Company intends to file a preliminary and definitive proxy statement. The definitive proxy statement and
Slide 3: Key Transaction Highlights
Key Transaction Highlights Certain Near-Term Value Validates 70 Years of Combines Board Conducted with Future Potential Innovation Complementary Comprehensive Upside Preserved Strengths Evaluation • All-cash deal delivers • Reflects Lantheus’ decades • Unites Curium's theranostics • Thoroughly evalu
Slide 4: Summary of Transaction Terms
Summary of Transaction Terms Acquirer Curium $102.50 per share in cash at close, plus non-transferable CVRs providing potential for up to $12.00 per share in additional cash payments Transaction Value Up to $114.50 per share in total consideration; up to ~$8 billion total transaction value Up to $8.
Slide 5: CVR Structure and Timelines
CVR Structure and Timelines Total Aggregate CVR Payment Contingent Value Right (CVR) 1 Franchise Sales Milestone (in cash) Measurement Period Non-transferable rights entitling shareholders to additional cash payments upon achievement of ≥ $950 M $1.00/share specified commercial milestones ≥ $1,100 M
Slide 6: About Curium
About Curium • A leading global radiopharmaceutical company with proven expertise in the development, manufacturing and supply of radiopharmaceuticals that improve the way cancer is diagnosed and treated • Proven track record of expanding access across 70+ countries in 6 continents • Significant glo
Slide 7: Combining Complementary Strengths to Expand Global Reach
Combining Complementary Strengths to Expand Global Reach Offer reflects value created by Lantheus More NDA approvals than any other radiopharmaceutical company including: through decades of leadership and innovation Lantheus led the renaissance in radiopharmaceuticals and brought radiodiagnostics in
Slide 8: Board Process Overview
Board Process Overview Board conducted a comprehensive Unanimously determined evaluation of its strategic options this transaction is in the best interests with the assistance from its financial of the company and its shareholders advisors • The Board approved a transaction structure • The Board's c
Slide 9: Two Pioneers In Radiopharmaceuticals Are Joining Forces
Two Pioneers In Radiopharmaceuticals Are Joining Forces Combining decades of achievement to bring innovative treatments to more patients around the world Value For Shareholders Complementary Strengths A natural fit, spanning the full spectrum All-cash CVRs provide Transaction of radiopharmaceutical
Slide 10: Lantheus Announces Definitive Agreement to Merge with Curium
Lantheus Announces Definitive Agreement to Merge with Curium Combined company would span full radiopharmaceutical value chain delivering nuclear medicine solutions to patients and healthcare systems across more than 70 countries August 3, 2026 © 2026 Lantheus. All rights reserved.
Lantheus Holdings — Merger or Acquisition (August 2026) on 6ix